Latest news with #GlenmarkPharma
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
Reuters
12-05-2025
- Business
- Reuters
Indian pharma stocks drop as Trump to sign executive order to cut prices of medicines
May 12 (Reuters) - Indian pharmaceutical stocks (.NIPHARM), opens new tab shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less. Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index (.NSEI), opens new tab was trading 2.4% higher. Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma ( opens new tab and Cipla ( opens new tab declined 0.4% and 1.5%, respectively. Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing. The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details. Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs. The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
Yahoo
12-05-2025
- Business
- Yahoo
Indian pharma stocks drop as Trump to sign executive order to cut prices of medicines
(Reuters) -Indian pharmaceutical stocks shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less. Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index was trading 2.4% higher. Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma and Cipla declined 0.4% and 1.5%, respectively. Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing. The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details. Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs. The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
5 stocks that look good on charts amid market volatility; check list here
Equity markets are likely to experience high volatility in the coming days amid fears of escalation of conflicts between India and Pakistan. That apart, the upcoming US Fed meeting outcome and FII trading activity may weigh on the market sentiment. As such, here are 5 stocks from the midcap and smallcap universe that look favourably placed on the technical charts. Glenmark Pharma Current Price: ₹ 1,408 Upside Potential: Support: ₹ 1,360 Resistance: ₹ 1,460; ₹ 1,490; ₹ 1,535 Glenmark Pharma stock is expected to trade with a favourable bias as long as the stock holds above ₹ 1,360 levels. On the upside, the stock can potentially surge to ₹ 1,670; with interim resistance likely around ₹ 1,460, ₹ 1,490 and ₹ 1,535 levels. Chambal Fertilisers Current Price: ₹ 707 Upside Potential: Support: ₹ 675 Resistance: ₹ 738; ₹ 767 Chambal Fertilisers has been trading at record high levels. The stock has significantly outperformed the benchmark indices, with a rally of over 43 per cent thus far in 2025, as against 3 per cent gain on the BSE Sensex and the NSE Nifty. CLICK HERE FOR THE CHART The price-to-moving averages action remains positive, as the stock trades firmly above its key moving averages across time-frames. The near-term bias for the stock is expected to remain positive as long as the stock holds above ₹ 675. On the upside, the stock can potentially soar to ₹ 807 levels, with interim resistance likely around ₹ 738 and ₹ 767 levels. ALSO READ: How can retail investors make money in the current markets? Max Healthcare Current Price: ₹ 1,159 Upside Potential: Support: ₹ 1,105; ₹ 1,090 Resistance: ₹ 1,207; ₹ 1,236 The near-term bias for Max Healthcare is expected to remain favourable as long as the stock holds above ₹ 1,104 - ₹ 1,090 support zone. On the upside, the stock can potentially target ₹ 1,275 levels, with interim resistance likely around ₹ 1,207 and ₹ 1,236 levels. CLICK HERE FOR THE CHART Blue Dart Express Current Price: ₹ 6,500 Upside Potential: Support: ₹ 6,340; ₹ 6,000 Resistance: ₹ 6,735; ₹ 6,930 Blue Dart stock is seen attempting to make higher highs and higher lows on the daily scale. Chart shows presence of near support at ₹ 6,340; and far-off support at ₹ 6,000-mark. On the upside, the stock may attempt a rally towards its 200-day Simple Moving Average (200-DSMA), which stands at ₹ 7,250 levels. Interim resistance for the stock can be anticipated at ₹ 6,735 and ₹ 6,930 levels. CLICK HERE FOR THE CHART CCL Products Current Price: ₹ 719 Upside Potential: Support: ₹ 693; ₹ 664 Resistance: ₹ 746; ₹ 790 CCL Products has given a fresh breakout on the daily scale in trades on Wednesday. The outlook for the stock is likely to remain upbeat as long as the stock holds above ₹ 693; below which support for the stock can be anticipated around its 200-DSMA at ₹ 664. On the upside, the stock can surge to ₹ 830 levels, with interim resistance likely around ₹ 746 and ₹ 790 levels.
